BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

This study is currently recruiting participants. (see Contacts and Locations)

Verified March 2014 by Massachusetts General Hospital

Sponsor:

Collaborators:

National Center for Medical Rehabilitation Research (NCMRR)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute on Deafness and Other Communication Disorders (NIDCD)

Department of Veterans Affairs

Information provided by (Responsible Party):

Leigh R. Hochberg, MD, PhD., Massachusetts General Hospital

ClinicalTrials.gov Identifier:

NCT00912041

First received: June 1, 2009

Last updated: March 24, 2014

Last verified: March 2014

History of Changes

Tracking Information

First Received Date ^ICMJE

June 1, 2009

Last Updated Date

March 24, 2014

Start Date ^ICMJE

May 2009

Estimated Primary Completion Date

September 2017 (final data collection date for primary outcome measure)

Current Primary Outcome Measures ^ICMJE

The primary endpoint of this Study is to determine the safety of the BrainGate2 Neural Interface System. [ Time Frame: One year post-implant evaluation period ] [ Designated as safety issue: Yes ]

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

Complete list of historical versions of study NCT00912041 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

To investigate the feasibility of BrainGate2 and to establish the parameters for a larger clinical study, such as appropriate neural decoding algorithms, sample size, indices of measurement, success criteria, and endpoints. [ Time Frame: Course of the study ] [ Designated as safety issue: No ]

Original Secondary Outcome Measures ^ICMJE

Same as current

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

Official Title ^ICMJE

BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

Brief Summary

The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility of efficacy) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.

Detailed Description

The goal of the BrainGate2 research and development project is to identify the core methods and features for a medical device that could allow people with paralysis to recover a host of abilities that normally rely on the hands.

Study Type ^ICMJE

Interventional

Study Phase

Not Provided

Study Design ^ICMJE

Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label

Condition ^ICMJE

Tetraplegia
Spinal Cord Injuries
Amyotrophic Lateral Sclerosis
Brain Stem Infarctions
Locked in Syndrome

Intervention ^ICMJE

Device: Placement of the BrainGate2 sensor into the motor cortex

The 4x4 mm BrainGate2 sensor is placed into the motor cortex, connected to a percutaneous pedestal. Neural recordings are made at least weekly for a year or more.

Other Names:

BrainGate
NeuroPort
neural prosthesis
neural prosthetic
neuroprosthetic
brain computer interface
brain-computer interface

Study Arm (s)

Not Provided

Publications *

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Recruiting

Estimated Enrollment ^ICMJE

Estimated Completion Date

December 2017

Estimated Primary Completion Date

September 2017 (final data collection date for primary outcome measure)

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Clinical diagnosis of spinal cord injury, brainstem stroke, muscular dystrophy, amyotrophic lateral sclerosis or other motor neuron disorders
Complete or incomplete tetraplegia (quadriplegia)
Must live within a three-hour drive of the Study site
(There are additional inclusion criteria)

Exclusion Criteria:

Visual impairment such that extended viewing of a computer monitor would be difficult even with ordinary corrective lenses
Chronic oral or intravenous steroids or immunosuppressive therapy
Other serious disease or disorder that could seriously affect ability to participate in the study
(There are additional exclusion criteria)

Gender

Both

Ages

18 Years to 75 Years

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact: Leigh R Hochberg, M.D., Ph.D.

617-726-4218

clinicaltrials@braingate2.org

Listed Location Countries ^ICMJE

United States

Removed Location Countries

Administrative Information

NCT Number ^ICMJE

NCT00912041

Other Study ID Numbers ^ICMJE

MGH-BG2-TP-001, R01DC009899, RC1HD063931

Has Data Monitoring Committee

Yes

Responsible Party

Leigh R. Hochberg, MD, PhD., Massachusetts General Hospital

Study Sponsor ^ICMJE

Leigh R. Hochberg, MD, PhD.

Collaborators ^ICMJE

National Center for Medical Rehabilitation Research (NCMRR)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute on Deafness and Other Communication Disorders (NIDCD)
Department of Veterans Affairs

Investigators ^ICMJE

Principal Investigator:

Leigh R Hochberg, M.D., PH.D.

Massachusetts General Hospital

Information Provided By

Massachusetts General Hospital

Verification Date

March 2014

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top